Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Regenerx Biopharmaceuticals Inc is a biopharmaceutical developer. It is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352, and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Rockville, MD, 20850